{"id":296012,"date":"2026-04-14T00:00:00","date_gmt":"2026-04-14T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneim0015-2024-biopharma-chronic-obstructive-pulmonary-disease-unmet-need-unmet-need-severe-to-very\/"},"modified":"2026-05-13T11:14:40","modified_gmt":"2026-05-13T11:14:40","slug":"unneim0015-2026-biopharma-chronic-obstructive-pulmonary-disease-unmet-need-unmet-need-severe-to-very-severe-chronic","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneim0015-2026-biopharma-chronic-obstructive-pulmonary-disease-unmet-need-unmet-need-severe-to-very-severe-chronic\/","title":{"rendered":"Chronic Obstructive Pulmonary Disease &#8211; Unmet Need &#8211; Unmet Need &#8211; Severe to Very Severe Chronic Obstructive Pulmonary Disease (US EU)"},"content":{"rendered":"<p>The severe to very severe chronic <abbr data-abbreviation-entity=\"4770\" title=\"chronic obstructive pulmonary disease\">COPD<\/abbr> market is crowded, with numerous <abbr data-abbreviation-entity=\"4874\" title=\"long-acting muscarinic antagonist\">LAMA<\/abbr>, <abbr data-abbreviation-entity=\"4873\" title=\"long-acting beta2 agonist\">LABA<\/abbr>\/<abbr data-abbreviation-entity=\"4859\" title=\"inhaled corticosteroid\">ICS<\/abbr>, <abbr data-abbreviation-entity=\"4873\" title=\"long-acting beta2 agonist\">LABA<\/abbr>\/<abbr data-abbreviation-entity=\"4874\" title=\"long-acting muscarinic antagonist\">LAMA<\/abbr>, and triple <abbr data-abbreviation-entity=\"4873\" title=\"long-acting beta2 agonist\">LABA<\/abbr>\/<abbr data-abbreviation-entity=\"4874\" title=\"long-acting muscarinic antagonist\">LAMA<\/abbr>\/<abbr data-abbreviation-entity=\"4859\" title=\"inhaled corticosteroid\">ICS<\/abbr> inhalers competing for use. Although dual and triple longacting bronchodilators remain the backbone of treatment, clinicians are increasingly interested in therapies that better address exacerbation risk, steroid responsiveness, and emerging inflammatory endotypes. Newer entrants, such as the biologics Dupixent (<abbr data-abbreviation-entity=\"4864\" title=\"interleukin\">IL<\/abbr>-4\u00a0 \/\u00a0<abbr data-abbreviation-entity=\"4864\" title=\"interleukin\">IL<\/abbr>-13 inhibitor) and Nucala (<abbr data-abbreviation-entity=\"4864\" title=\"interleukin\">IL<\/abbr>-5 inhibitor) and the dual <abbr data-abbreviation-entity=\"5503\" title=\"phosphodiesterase\">PDE<\/abbr>3 \/\u00a0<abbr data-abbreviation-entity=\"5503\" title=\"phosphodiesterase\">PDE<\/abbr>4 inhibitor Ohtuvayre, signal a meaningful shift that may reshape the competitive landscape over the next ten years. Yet, despite expanding options, no available therapy can halt <abbr data-abbreviation-entity=\"4770\" title=\"chronic obstructive pulmonary disease\">COPD<\/abbr> progression or repair damaged lung tissue. Current treatments primarily relieve symptoms, but patients\u2019 quality of life still suffers, and the disease remains one of the leading causes of death worldwide. Many patients, particularly those with severe disease, are inadequately controlled. As a result, substantial unmet need persists for more effective, disease-modifying therapies.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>Which drug attributes, such as improvement in lung function, reduction of exacerbation rates, and ease of administration, most influence pulmonologists\u2019 prescribing decisions for severe to very severe <abbr data-abbreviation-entity=\"4770\" title=\"chronic obstructive pulmonary disease\">COPD<\/abbr>? Which have limited impact, and which are hidden opportunities?<\/li>\n<li>How do current therapies, such as GSK\u2019s Anoro, Trelegy, and Nucala; AstraZeneca\u2019s Symbicort and Breztri \/ Trixeo; Sanofi \/ Regeneron\u2019s Dupixent; and Merck\u2019s Ohtuvayre perform on these attributes?<\/li>\n<li>What trade-offs across clinical and nonclinical attributes and price are acceptable to U.S. and European pulmonologists for a hypothetical new <abbr data-abbreviation-entity=\"4770\" title=\"chronic obstructive pulmonary disease\">COPD<\/abbr> drug?<\/li>\n<\/ul>\n<p><strong>Product description<\/strong><\/p>\n<p><a>Unmet Need offers insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities, enabling you to:<\/a><\/p>\n<ul class=\"round-bullets\">\n<li>Evaluate clinical and nonclinical product attributes that influence treatment decisions through physicians\u2019 weightings and analysis of stated vs. derived importance.<\/li>\n<li>Pinpoint areas of high unmet need by assessing current drug performance against key attributes and treatment drivers.<\/li>\n<li>Analyze market scenarios for different target product profiles using the TPP Simulator.<\/li>\n<\/ul>\n<p><b>Publication date<\/b><\/p>\n<p>April 2026<\/p>\n<p><b>Geography<\/b><\/p>\n<p>United States, France, Germany, United Kingdom<\/p>\n<p><strong>Primary research<\/strong><\/p>\n<p>Survey of 60 U.S. and 30 European pulmonologists<\/p>\n<p><strong>Key drugs covered<\/strong><\/p>\n<p>Dupixent, Nucala, Ohtuvayre, Trelegy, Breztri \/ Trixeo<\/p>\n<p><strong>Key analyses<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>Importance of clinical and nonclinical product attributes to physicians<\/li>\n<li>Assessment of current drug performance against treatment drivers and goals<\/li>\n<li>Physician perceptions of unmet needs in the indication and related indications<\/li>\n<li>Remaining drug development opportunities<\/li>\n<\/ul>\n<p><strong>Key feature<\/strong><\/p>\n<p>Target Product Profile (TPP) simulator tool allows for customizable market simulations based on conjoint analysis. Compare up to seven TPPs across multiple disease-specific attributes and price points to gauge which variables influence prescribing behavior.<\/p>\n","protected":false},"template":"","class_list":["post-296012","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-chronic-obstructive-pulmonary-disease","biopharma-therapy-areas-respiratory","biopharma-product-unmet-need","biopharma-geography-us","biopharma-date-2609"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/296012","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":4,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/296012\/revisions"}],"predecessor-version":[{"id":578477,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/296012\/revisions\/578477"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=296012"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}